This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Hikma Pharmaceuticals USA Inc.
Hikma Pharmaceuticals USA Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America. Founded in 1978, Hikma has established itself as a leader in the development and manufacturing of generic and branded medications, with a strong focus on injectable products and complex generics. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio that includes critical care medications and specialty pharmaceuticals. Hikma's strategic position in the market is underscored by its notable achievements, including significant growth in both revenue and product offerings. With a dedication to improving patient outcomes, Hikma Pharmaceuticals continues to make a meaningful impact in the healthcare sector.
DitchCarbon Score
How does Hikma Pharmaceuticals USA Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharmaceuticals USA Inc.'s score of 28 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikma Pharmaceuticals USA Inc. currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Hikma Pharmaceuticals PLC, which may influence its climate commitments and performance metrics. As part of its corporate family, Hikma Pharmaceuticals USA Inc. inherits climate-related data and initiatives from Hikma Pharmaceuticals PLC. However, no specific reduction targets or climate pledges have been outlined for the US subsidiary. The lack of documented reduction initiatives suggests that the company may still be in the early stages of formalising its climate strategy. In the broader context, the pharmaceutical industry is increasingly focusing on sustainability and carbon reduction, with many companies setting Science-Based Targets (SBTi) to align with global climate goals. While Hikma Pharmaceuticals USA Inc. has not yet established its own targets, it is essential for the company to consider adopting similar initiatives to enhance its environmental performance and contribute to industry-wide efforts in combating climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikma Pharmaceuticals USA Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
